HIV/AIDS: Pneumocystis jiroveci pneumonia (PCP) Prophylaxis
-
Percentage of patients aged 6 weeks or older with a diagnosis of HIV/AIDS, who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis
CBE ID0405
Percentage of patients aged 6 weeks or older with a diagnosis of HIV/AIDS, who were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis
Percentage of patients, aged 13 years and older, who were screened for high risk sexual behaviors at least once within 12 months.
Percentage of patients, aged 13 years and older, who were screened for injection drug use at least once within 12 months.
Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS for whom syphilis screening was performed during the measurement year
Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS, who have received chlamydia, gonorrhea, and syphilis screenings at least once since the diagnosis of HIV infection
Percentage of patients aged 3 months and older with a diagnosis of HIV/AIDS, for whom there was documentation that a tuberculosis (TB) screening test was performed and results interpreted (for tuberculin skin tests) at least once since the diagnosis of HIV infection.
Percentage of hospice or palliative care patients who were screened for dyspnea during the hospice admission evaluation / palliative care initial encounter.
Percentage of patients who screened positive for dyspnea who received treatment within 24 hours of screening.
This quality measure is defined as:
Percentage of hospice or palliative care patients who screened positive for pain and who received a clinical assessment of pain within 24 hours of screening.
Percentage of hospice or palliative care patients who were screened for pain during the hospice admission evaluation / palliative care initial encounter.